🇩🇰 Ousia Pharma secures seed funding to advance novel obesity treatment

21

Ousia2025_walking.jpeg

Ousia Pharma, a Danish biotech company pioneering peptide-drug conjugates for metabolic diseases, has announced the successful closing of a significant seed financing round. The round was led exclusively by Omega Funds and will support the preclinical and early clinical development of Ousia’s innovative dual-incretin-NMDA receptor antagonist conjugate for obesity treatment.Ousia Pharma+1Ousia Pharma+1

This novel therapeutic approach aims to deliver small-molecule neuroplasticity modulators directly to the brain’s appetite control centers, potentially offering improved efficacy and tolerability over existing treatments.

“We are excited to enter the next phase of Ousia Pharma’s journey, advancing our groundbreaking platform towards clinical development,” said Anders B. Klein, PhD, CEO of Ousia Pharma.

In conjunction with the financing, Ousia Pharma has expanded its Board of Directors to include:

  • Prof. Sir Mene Pangalos, former EVP of BioPharmaceuticals R&D at AstraZeneca

  • Dr. Elisabeth Björk, former SVP of Cardiovascular, Renal, and Metabolism R&D at AstraZeneca

  • Dr. Otello Stampacchia, Founder and Managing Director of Omega FundsOusia Pharma+1Ousia Pharma+1Ousia Pharma+1Ousia Pharma+1

These additions join existing board members Ian Laquian, CEO of Kariya Pharmaceuticals, and Christoffer Clemmensen, Associate Professor at the University of Copenhagen and Ousia’s CSO.Ousia Pharma+1Ousia Pharma+1

Ousia Pharma was founded in 2022, emerging from research conducted at the University of Copenhagen. The company’s mission is to develop effective and safe pharmacotherapies to improve the health and lives of people living with cardiometabolic diseases.Ousia Pharma+1Ousia Pharma+1

For more information, visit Ousia Pharma’s official website.

Originally published on 7 May by Ousia Pharma.

Announcements are published as a service to readers. The sender is responsible for all content.

Announcements for publication can be submitted to in**@*********ay.com.